WO2019039937A8 - Therapeutic combination for cancer treatment - Google Patents

Therapeutic combination for cancer treatment Download PDF

Info

Publication number
WO2019039937A8
WO2019039937A8 PCT/NL2018/050547 NL2018050547W WO2019039937A8 WO 2019039937 A8 WO2019039937 A8 WO 2019039937A8 NL 2018050547 W NL2018050547 W NL 2018050547W WO 2019039937 A8 WO2019039937 A8 WO 2019039937A8
Authority
WO
WIPO (PCT)
Prior art keywords
cancer treatment
therapeutic combination
cancer
medicament
composition
Prior art date
Application number
PCT/NL2018/050547
Other languages
French (fr)
Other versions
WO2019039937A1 (en
Inventor
Gerrit Jansen
Godefridus Johannes PETERS
Gerrit Johan Ossenkoppele
Original Assignee
Stichting Vumc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stichting Vumc filed Critical Stichting Vumc
Publication of WO2019039937A1 publication Critical patent/WO2019039937A1/en
Publication of WO2019039937A8 publication Critical patent/WO2019039937A8/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention relates to a composition comprising a statin and an aminopeptidase inhibitor. Said composition may be used as a medicament, including in a method of treating cancer, such as a hematological cancer. The invention further relates to methods of treating a cancer in an individual, and to a use of an aminopeptidase inhibitor in a method for the preparation of a medicament for the treatment of a cancer.
PCT/NL2018/050547 2017-08-21 2018-08-20 Therapeutic combination for cancer treatment WO2019039937A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17187127 2017-08-21
EP17187127.0 2017-08-21

Publications (2)

Publication Number Publication Date
WO2019039937A1 WO2019039937A1 (en) 2019-02-28
WO2019039937A8 true WO2019039937A8 (en) 2019-03-28

Family

ID=59677154

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NL2018/050547 WO2019039937A1 (en) 2017-08-21 2018-08-20 Therapeutic combination for cancer treatment

Country Status (1)

Country Link
WO (1) WO2019039937A1 (en)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0759507B2 (en) * 1989-02-23 1995-06-28 日本化薬株式会社 Myelodysplastic syndrome therapeutic agent
US5162117A (en) 1991-11-22 1992-11-10 Schering Corporation Controlled release flutamide composition
US5260069A (en) 1992-11-27 1993-11-09 Anda Sr Pharmaceuticals Inc. Pulsatile particles drug delivery system
NZ506293A (en) 1998-03-12 2003-05-30 British Biotech Pharm Cytostatic agents
US20130023513A1 (en) * 2010-01-12 2013-01-24 Hughes Thomas E Methods and Compositions for Treating Cardiovascular Disorders
WO2011085473A1 (en) * 2010-01-13 2011-07-21 Linda Penn Treating cancer with statins and compounds having dipyridamole activity

Also Published As

Publication number Publication date
WO2019039937A1 (en) 2019-02-28

Similar Documents

Publication Publication Date Title
MX2021013830A (en) Ezh2 inhibitors for treating lymphoma.
PH12018500097A1 (en) Combination of pd-1 antagonist with an egfr inhibitor
PH12018500642A1 (en) Anti-garp antibody
SG10201811841UA (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
SG10201811128RA (en) Ezh2 inhibitors for treating lymphoma
MX2021006734A (en) Method for treating cancer.
PH12016502355A1 (en) Pharmaceutical composition
WO2013024282A3 (en) Inhibitor or down- regulator of the expression of one or both of tbk1 ikk-epsilon for use in the treatment of pi3kinase dependent cancer
WO2015054619A8 (en) Use of a pcsk9 inhibitor to treat hyperlipidemia
EP4140487A8 (en) Combination therapy for treating cancer
EA201790142A1 (en) TREATMENT OF LEUKEMIA INHIBITORS HISTONDEACETYLASE
MX363243B (en) Compositions and methods for treating cancer.
MX2018002344A (en) Method for treating cancer.
PH12016502352A1 (en) Pharmaceutical composition
TW201613578A (en) Pharmaceutical combinations
MX2020001727A (en) Combination therapy.
MX2019013862A (en) Combination therapy.
PH12019500758A1 (en) Pharmaceutical compositions and methods for the treatment of cancer
MX2020011817A (en) Methods for treating lymphoma.
MX2022014792A (en) Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same.
MX2018004296A (en) Combination of an il-2rbeta-selective agonist and a long-acting il-15 agonist.
MX2019010218A (en) Pyrazole derivatives as bromodomain inhibitors.
WO2015156674A3 (en) Method for treating cancer
EP2786765A3 (en) Composition for combination therapy comprising an anti-C-met antibody and a FGFR inhibitor
MX2020012782A (en) Ccr5 inhibitor for use in treating cancer.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18766384

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18766384

Country of ref document: EP

Kind code of ref document: A1